Dogwood Therapeutics 1Q 2026: Revenue $2.41M, EPS ($0.15) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Dogwood Therapeutics reported Q1 2026 revenue of $2.41M, with a net loss of $4.99M and diluted EPS of ($0.15), showing significant improvement year-over-year. The company is advancing its clinical programs, including the ongoing Phase 2b trial of Halneuron® and a new program for CIPN. Recent equity financing has extended operational funding into Q4 2026. Halneuron® has received FDA fast-track designation, although risks remain regarding clinical and market setbacks.
Dogwood Therapeutics reported first-quarter 2026 results with revenue of $2.41M and a net loss attributable to common stockholders of ($4.99M), or diluted EPS of ($0.15), improving versus the prior-year quarter as the company advances clinical programs and completed equity financings in January 2026.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $2.41M | $1.99M | 20.8% |
| Net income² | ($4.99M) | ($12.18M) | 59.1% |
| Diluted EPS³ | ($0.15) | ($8.45) | 98.2% |
¹ Reported as “Revenue”. ² Reported as “Net loss attributable to common stockholders”. ³ Reported as “loss per common share, basic and diluted”.
Business Highlights
- Pipeline progress: Halneuron® Phase 2b ongoing with 164 patients enrolled; top-line data expected in fall 2026 and interim results showed a treatment effect.
- New program: SP16 IV licensed for chemotherapy-induced peripheral neuropathy (CIPN); IND accepted by the FDA and NCI-funded Phase 1b dosing expected to start mid-2026.
- Portfolio optimization: Rights to IMC-1 and IMC-2 assigned to PRIDCor while Dogwood retains tiered royalties and potential participation in future financing.
- Operational funding: January 2026 equity offerings provided approximately $11.4M in net cash, extending runway into Q4 2026 to support ongoing trials.
- Regulatory: Halneuron® granted FDA fast-track designation for CINP; company notes IPR&D and goodwill could be at risk if clinical or market setbacks occur.
Original SEC Filing: Dogwood Therapeutics, Inc. [ DWTX ] - 10-Q - May. 15, 2026